Tarku Resources Ltd (TRKUF): $TRKUF: Super hot Silver Mining Play her...

$TRKUF: Super hot Silver Mining Play here............

makinezmoney · 2022-02-25T20:35:30.7800000Z

$TRKUF: Super hot Silver Mining Play here............ Silver reaching new highs........ now at $0.05 https://www.tarkuresources.com/wp-content/uploads/21-10-12-Tarku-Resources-Presentation-Recent-Update.pdf GO $TRKUF

Play Episode

7min

Proactive - Interviews for investors

Graphene Manufacturing Group advances aluminium-ion battery development with key U.S. partnership

Graphene Manufacturing Group CEO Craig Nicol joined Steve Darling from Proactive to share an update as the company continues to make strides in the development of its Graphene Aluminium-Ion Battery technology, a cutting-edge innovation being pursued in collaboration with the University of Queensland and Rio Tinto under a Joint Development Agreement. Nicol told Proactive, to accelerate battery development, GMG has signed a service contract with the Battery Innovation Center (BIC) in Indiana, USA. This partnership will support the next phase of research and optimization, leveraging BIC’s state-of-the-art 40,000-square-foot facility in Newberry, Indiana. As a globally recognized innovation hub, BIC specializes in advancing battery technologies, offering end-to-end support from research and development to prototype manufacturing and low-volume production—a critical advantage for GMG as it scales up its graphene-based energy storage solutions. Nicol emphasized that collaborating with BIC allows GMG to access advanced battery manufacturing infrastructure without incurring the high capital costs of building its own pilot production facility—an investment that could exceed AU$10 million. Through this agreement, GMG will retain full intellectual property (IP) rights over the battery development work, ensuring control over its proprietary technology while optimizing BIC’s cell design expertise and battery manufacturing capabilities. By integrating BIC’s expertise into its scale-up strategy, GMG can streamline the production of sample battery cells before committing to mass production, reducing risks and deferring large capital expenditures until the technology reaches a higher level of readiness. Looking ahead, GMG aims to optimize battery performance, produce initial test cells this year, and engage customers for validation. Nicol noted strong interest from major companies eager to integrate this technology. #proactiveinvestors #graphenemanufacturinggroupltd #BatteryTech #

Proactive - Interviews for investors

Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Proactive - Interviews for investors

Empire Metals MD on high-purity titanium breakthrough

Empire Metals Ltd (AIM:EEE) managing director Shaun Bunn talked with Proactive about the company's latest metallurgical test results at the Pitfield project. The test work delivered an impressive 91.6% purity titanium dioxide compound—achieved on the first attempt. Bunn emphasised that this high-grade product is free from deleterious contaminants, making it suitable for further processing into titanium sponge metal or premium-grade titanium pigments. He explained that the team successfully extracted and refined the titanium-bearing minerals using gravity separation, flotation, and acid digestion techniques. The company is now focused on optimising its processing flow sheet and scaling up test work. Recent bulk metallurgical sample collections at Pitfield will support larger-scale testing, with the goal of producing more of this high-grade product for market analysis. Bunn also highlighted that the simplicity of Pitfield's mineral composition, free from heavy metals or radioactive elements, has contributed to the rapid progress in refining processes. With further purification testing ahead, Empire Metals is poised to advance its titanium strategy. For more insights from this interview, visit Proactive’s YouTube channel. Don't forget to like, subscribe, and turn on notifications for future updates. #EmpireMetals #Titanium #Mining #PitfieldProject #Metallurgy #TitaniumDioxide #MineralProcessing #MiningStocks #TitaniumSponge #Investing

Followers	1337
Posts	27413
Boards Moderated	29
Alias Born	12/10/2012

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free